Saturday, July 2, 2016

JMP resumes coverage of AtriCure

JMP resumes coverage of AtriCure

June 30, 2016 by · Leave a Comment 

Tweet JMP Securities resumed coverage of AtriCure (NASDAQ:ATRC) with a “market outperform” rating and $25 price target. The stock closed at $14.39 on Wednesday. “AtriCure is well positioned, in our view, to further develop and penetrate several large opportunities that are currently underserved in and around atrial fibrillation (AF),” writes analyst John Gillings. “We believe […]

Rodman starts Catalyst Biosciences at buy

Rodman starts Catalyst Biosciences at buy

June 30, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday. Using its proprietary protease platform, Catalyst Biosciences is advancing its lead hemostasis programs for hemophilia A and B, as well as its anti- complement programs, which could […]

Rodman starts OpGen at buy

Rodman starts OpGen at buy

June 29, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and 12-month price target of $2.50. The stock closed at $1.56 on Tuesday. “In our view, the company’s QuickFISH assays, the latest generation of its fluorescence in situ hybridization (FISH) platform, are differentiated from competitors in that they utilize the unique […]

HCW starts Vascular Biogenics at buy

HCW starts Vascular Biogenics at buy

June 29, 2016 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Vascular Biogenics (NASDAQ:VBLT) with a “buy” rating and 12-month price target of $11. The stock closed at $4.10 on Tuesday. Vascular Biologics, also known as VBL Therapeutics or VBL, is developing a novel anti-angiogenesis therapy for the treatment of solid tumors. Anti-angiogenesis therapies are currently the standard of […]

Rodman starts NeuroMetrix at buy

Rodman starts NeuroMetrix at buy

June 29, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of NeuroMetrix (NASDAQ:NURO) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.74 on Tuesday. NeuroMetrix is a commercial-stage medical device company aimed at management of chronic intractable pain due to conditions such as diabetes, fibromyalgia and arthritis. “In our view, the company’s […]

Titan Pharma added to Russell 3000 index

Titan Pharma added to Russell 3000 index

June 27, 2016 by · Leave a Comment 

Tweet Titan Pharmaceuticals (NASDAQ:TTNP) has been added to the broad U.S. market Russell 3000 index and the small-cap Russell 2000 index as part of Russell Investments’ annual reconstitution of its stock indexes, effective at the opening today. “We are very pleased to be added to the Russell 3000 and 2000 indexes and we look forward […]

Stifel starts Clearside Biomedical at buy

Stifel starts Clearside Biomedical at buy

June 27, 2016 by · Leave a Comment 

Tweet Stifel has launched coverage of Clearside Biomedical (NASDAQ:CLSD) with a “buy” rating and 12-month target price of $13. The stock closed at $6.80 on Friday. Clearside has developed a novel ocular injection platform to deliver drug optimally throughout the eye by way of the suprachroidal space (SCS). “With exclusive claims to this drug delivery, […]

Cellectar shows potential against triple negative breast cancer

Cellectar shows potential against triple negative breast cancer

June 23, 2016 by · Leave a Comment 

Tweet Cellectar Biosciences (NASDAQ:CLRB) has announced the results of the first phase of a NCI-funded Small Business Innovation Research (SBIR) Phase 1 contract for a study of CLR 125, a radiotherapeutic isotope, which may be suited to treat micro-metastatic disease, conjugated to the company’s proprietary phospholipid drug conjugate (PDC) delivery platform. The study demonstrated that […]

Titan Medical CEO resigns as director following AGM vote

Titan Medical CEO resigns as director following AGM vote

June 23, 2016 by · Leave a Comment 

Tweet At the annual meeting of Titan Medical (TSX:TMD), shareholders voted against reelecting John Hargrove, CEO and chairman, as a director. Mr. Hargrove received 42% of votes cast in favor of reelection and 58% against. Following the meeting, Mr. Hargrove tendered his resignation as a director of Titan Medical in accordance with the company’s majority […]

Anavex gets orphan drug status for infantile spasms

Anavex gets orphan drug status for infantile spasms

June 22, 2016 by · Leave a Comment 

Tweet Anavex Life Sciences (NASDAQ:AVXL) has received FDA orphan drug designation for ANAVEX 2-73 for the treatment of infantile spasms. ANAVEX 2-73 already has orphan drug designation for the treatment of Rett syndrome. An infantile spasm is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. […]

Next Page »

Email Newsletters with Constant Contact
Google+